Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure

Kramer, 1983, Controlled trial of Captopril in chronic heart failure: a rest and exercise hemodynamic study, Circulation, 67, 807, 10.1161/01.CIR.67.4.807 Davis, 1979, Treatment of chronic congestive heart failure with Captopril, an oral inhibitor of angiotensin converting enzyme, N Engl J Med, 301, 117, 10.1056/NEJM197907193010301 Tarazi, 1979, Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure, Am J Cardiol, 44, 1013, 10.1016/0002-9149(79)90237-6 Ader, 1980, Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor, Circulation, 61, 931, 10.1161/01.CIR.61.5.931 Levine, 1980, Acute and long-term response to oral converting-enzyme inhibitor, Captopril, in congestive heart failure, Circulation, 62, 35, 10.1161/01.CIR.62.1.35 Dzau, 1980, Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure, N Engl J Med, 302, 1373, 10.1056/NEJM198006193022501 Faxon, 1981, Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of Captopril with observations on sustained therapy, Am Heart J, 101, 548, 10.1016/0002-8703(81)90220-9 Maslowski, 1981, Hemodynamic, humoral, and electrolyte responses to Captopril in resistant heart failure, Lancet, 1, 71, 10.1016/S0140-6736(81)90004-0 Awan, 1981, Efficacy of oral angiotensin-converting enzyme inhibitor with Captopril therapy in severe chronic heart failure, Am Heart J, 101, 22, 10.1016/0002-8703(81)90379-3 Massie, 1982, Hemodynamic and radionuclide effects of acute Captopril therapy for heart failure: changes in left and right ventricular volumes and function at rest and during exercise, Circulation, 65, 1375, 10.1161/01.CIR.65.7.1374 Chatterjee, 1980, Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects, Ann Intern Med, 92, 600, 10.7326/0003-4819-92-5-600 Franciosa, 1977, Hemodynamic improvement after oral hydralazine in left ventricular failure, Ann Intern Med, 86, 388, 10.7326/0003-4819-86-4-388 Massie, 1977, Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure, Am J Cardiol, 40, 794, 10.1016/0002-9149(77)90199-0 Pierpont, 1980, Effect of hydralazine on renal function in patients with congestive heart failure, Circulation, 61, 323, 10.1161/01.CIR.61.2.323 Packer, 1982, Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure, N Engl J Med, 306, 57, 10.1056/NEJM198201143060201 Packer, 1981, Determinants of drug response in severe chronic heart failure. I. Activation of vasoconstrictor forces during vasodilator therapy, Circulation, 64, 506, 10.1161/01.CIR.64.3.506 Colucci, 1981, Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure, Am J Med, 71, 89, 10.1016/0002-9343(81)90263-1 Zelis, 1968, A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure, J Clin Invest, 47, 960, 10.1172/JCI105788 Packer, 1980, Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure, N Engl J Med, 303, 250, 10.1056/NEJM198007313030503 Packer, 1980, Dose requirements of hydralazine in patients with severe chronic congestive heart failure, Am J Cardiol, 45, 655, 10.1016/S0002-9149(80)80019-1 Massie, 1981, Postural hypotension and tachycardia during vasodilator therapy for chronic heart failure, Circulation, 63, 658, 10.1161/01.CIR.63.3.658 Massie, 1981, Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements, Circulation, 63, 269, 10.1161/01.CIR.63.2.269 Packer, 1982, Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure, Prog Cardiovasc Dis, 24, 275, 10.1016/0033-0620(82)90006-8